CRISPR Therapeutics AG (CRSP) EBT (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted EBT of -$122.1 million for Q1 2026, up 24.88% sequentially from -$162.5 million in Q4 2025, and up 9.49% YoY from -$111.5 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) EBT (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported EBT for 12 years, with the latest figure at -$122.1 million in Q1 2026.
- Quarterly EBT rose 9.49% year-over-year to -$122.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$597.7 million (down 2790.87% YoY) and the FY2025 annual result came in at -$610.5 million, down 1580.63% from the prior year.
- EBT improved to -$122.1 million in Q1 2026 per CRSP's latest filing, from -$162.5 million in the prior quarter.
- Over five years, EBT peaked at $367.3 million in Q4 2024 and troughed at -$207.3 million in Q2 2025.
- A 5-year average of -$87.8 million and a median of -$120.1 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT surged 310.01% in 2024, then slumped 144.25% in 2025.
- Over 5 years, EBT stood at -$120.1 million in 2022, then surged by 174.62% to $89.6 million in 2023, then soared by 310.01% to $367.3 million in 2024, then plunged by 144.25% to -$162.5 million in 2025, then gained by 24.88% to -$122.1 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$122.1 million, -$162.5 million, and -$105.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -90.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -90.19 Mn |
| Mar 31, 2026 | -122.09 Mn |
| Dec 31, 2025 | -162.53 Mn |
| Sep 30, 2025 | -105.82 Mn |
| Jun 30, 2025 | -207.26 Mn |
| Mar 31, 2025 | -134.89 Mn |
| Dec 31, 2024 | 367.29 Mn |
| Sep 30, 2024 | -85.07 Mn |
| Jun 30, 2024 | -125.12 Mn |
| Mar 31, 2024 | -115.87 Mn |
| Dec 31, 2023 | 89.58 Mn |
| Sep 30, 2023 | -111.74 Mn |
| Jun 30, 2023 | -76.82 Mn |
| Mar 31, 2023 | -51.75 Mn |
| Dec 31, 2022 | -120.05 Mn |
| Sep 30, 2022 | -175.12 Mn |
| Jun 30, 2022 | -179.72 Mn |
| Mar 31, 2022 | -175.61 Mn |
| Dec 31, 2021 | -143.50 Mn |
| Sep 30, 2021 | -127.75 Mn |